On May 21, 2020 OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that it will present new pre-clinical data demonstrating the utility of OncoSec’s next-generation product candidate, TAVOPLUS (enhanced interleukin-12 or "IL-12" plasmid), and its electroporation gene delivery system as a promising approach for patients with melanoma and other solid tumors (Press release, OncoSec Medical, MAY 21, 2020, View Source [SID1234558379]). The data were selected for two late-breaking poster presentations at the American Association for Cancer (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held June 22-24, 2020.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following posters will be presented during the session titled, Late-Breaking Research: Immunology 2, on June 22, 2020 from 9:00 a.m. – 6:00 p.m. EDT:
Title: Intratumoral electroporation of plasmid-encoded IL-12 and membrane-bound anti-CD3 increases tumor immunogenicity and augments the function of T cell subsets
Poster Number: 14
Abstract Number: LB-390
Title: Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of CXCL9 synergizes with IL-12 gene therapy (TAVO) to elicit robust anti-tumor immunity
Poster Number: 20
Abstract Number: LB-396
Full abstracts are available online at www.aacr.org. Posters will be available on OncoSec’s website following the presentations.